Lung Inflammation in Health and Disease, Volume I

Respiratory diseases are the leading causes of death and disability globally, with 65 million people suffering from COPD and 334 million from asthma. Systemic inflammation may induce and exacerbate local inflammatory diseases in the lungs, and the co-morbidity of two or more local inflammatory diseases often occurs. Current treatment options for lung disease are neither effective nor condition-specific, and there is a desperate need for novel therapeutics. Great progress has been made in recent years in many areas of the field, particularly in understanding the molecular geneses, regulatory mechanisms, signaling pathways, and cellular processes within lung disease. This is the first text to aggregate these developments, and the editors hope it will help to direct future research and result in the development of novel therapeutics.

Format: Paperback / softback
Length: 409 pages
Publication date: 02 April 2022
Publisher: Springer Nature Switzerland AG

Respiratory diseases are a major global cause of death and disability, affecting millions of people worldwide. COPD, a chronic respiratory condition, affects around 65 million individuals, while asthma, the most prevalent chronic disease, impacts 334 million people. Each year, tens of millions of people develop and succumb to respiratory infections like pneumonia and tuberculosis. Furthermore, systemic inflammation can exacerbate local lung inflammation, leading to a vicious cycle of disease progression.

Growing evidence suggests that patients with asthma, COPD, and other lung diseases exhibit both systemic and local inflammation. Co-morbidity of two or more local inflammatory diseases is common, with rheumatoid arthritis frequently coexisting with pulmonary hypertension, significantly impacting quality of life and potentially resulting in death. Current treatment options for lung disease are limited and often ineffective, particularly for patients with coexistent conditions.

There is a pressing need for novel therapeutics in the field of lung disease. The molecular and physiological understanding of most major lung diseases remains incomplete, further hindering the development of effective treatments. However, significant progress has been made in recent years in various areas of lung research.

Experts from around the world have contributed to two comprehensive volumes that highlight state-of-the-art advances in the study of lung disease. These volumes cover a wide range of topics, including molecular genetics, regulatory mechanisms, signaling pathways, and cellular processes within the lung. They also explore basic and clinical technology, drug discovery, diagnostics, treatment options, and predictive prognoses.

By consolidating these developments, this text serves as a valuable resource for researchers, clinicians, and healthcare professionals seeking to better understand and treat lung diseases. It provides a comprehensive overview of the current state of knowledge and highlights promising avenues for future research and innovation.

Weight: 810g
Dimension: 254 x 178 (mm)
ISBN-13: 9783030630485
Edition number: 1st ed. 2021